US biotech Oblenio Bio raises US$62m Series B for an autoimmune T-cell engager optioned from China's Leads Biolabs Pfizer Ventures leads with Deep Track, GV and Aditum; the asset LBL-051 comes from Nanjing's Leads Biolabs, another China-discovered drug advanced through a US company 誰の金か ·5 論調 ·7月2日